VEGFR(血管内皮生长因子受体)
VEGFR are receptors for vascular endothelial growth factor and belong to receptor tyrosine kinases.
- Cat.No. 产品名称 Information
-
GC26063
WAY-340935
WAY-340935 (VEGFR2-IN-2) can inhibit the function of VEGFR2 and the anti-proliferative activity against the H460 cell line is produced partly by interaction of VEGFR protein.
-
GC25969
SU5208
SU5208(3-[(Thien-2-yl)methylene]-2-indolinone) is an inhibitor of vascular endothelial growth factor receptor-2 (VEGFR2).
-
GC25092
Apatinib (YN968D1) mesylate
Apatinib mesylate (YN968D1, Rivoceranib) is a potent inhibitor of the VEGF signaling pathway with IC50 values of 1 nM, 13 nM, 429 nM and 530 nM for VEGFR-2, Ret (c-Ret), c-Kit and c-Src, respectively. Apatinib mesylate induces both autophagy and apoptosis.
-
GC25073
Anlotinib (AL3818) dihydrochloride
Anlotinib (AL3818) is a highly potent and selective VEGFR2 inhibitor with IC50 less than 1 nM. It has broad-spectrum antitumor potential in clinical trials. Please use saline solution rather than PBS for dilutions. PBS may cause precipitation.
-
GC25017
4,4'-Bis(4-aminophenoxy)biphenyl
4,4'-Bis(4-aminophenoxy)biphenyl is a monomer for polyimide production.
-
GC67948
Cabozantinib-d6
-
GC66043
VEGFR-2-IN-29
-
GC65335
PTC299
A DHODH inhibitor
-
GC64996
Tivozanib hydrochloride hydrate
-
GC64950
ODM-203
A dual inhibitor of VEGFR and FGFR
-
GC64895
Regorafenib-d3
-
GC64836
Famitinib
-
GC64346
Pegaptanib sodium
-
GC64205
VEGFR-3-IN-1
-
GC63805
4SC-203
4SC-203 (SC71710) is a multikinase inhibitor with potential antineoplastic activity. 4SC-203 selectively inhibits FMS-related tyrosine kinase 3 (FLT3/STK1), FLT3 mutated forms, and vascular endothelial growth factor receptors (VEGFRs).
-
GC49700
Takeda-6d
A dual inhibitor of RAF kinases and VEGFR2
-
GC49686
N-desmethyl Regorafenib N-oxide
An active metabolite of regorafenib
-
GC63214
Telatinib mesylate
A multi-kinase inhibitor
-
GC62291
(Z)-Orantinib
-
GC62185
Axitinib-d3
-
GC62145
Chiauranib
Chiauranib (CS2164) selectively inhibits multiple kinase targets aurora B kinase (AURKB), colony-stimulating factor 1 receptor (CSF1R), and vascular endothelial growth factor receptor (VEGFR)/platelet-derived growth factor receptor (PDGFR)/c-Kit , thereby inhibiting the rapid proliferation of tumor cells, enhancing the antitumor immunity, and inhibiting tumor angiogenesis, to achieve the anti-tumor efficacy.
-
GC61780
SU5204
SU5204 is a tyrosine kinase inhibitor with IC50 of 4 μM and 51.5 μM for FLK-1 (VEGFR-2) and HER2, respectively.
-
GC61600
VEGFR-2-IN-6
-
GC61454
GW806742X hydrochloride
-
GC48118
Sunitinib-d10
An internal standard for the quantification of sunitinib
-
GC60726
CP-547632 TFA
A potent inhibitor of VEGFR2 and bFGF
-
GC60365
TIE-2/VEGFR-2 kinase-IN-1
-
GC60283
Pentagamavunon-1
-
GC50330
BMS 605541
Potent VEGFR-2 inhibitor
-
GC50233
Vatalanib succinate
Potent VEGFR inhibitor; also aromatase inhibitor
-
GC50028
ZM 306416 hydrochloride
A VEGF receptor kinase inhibitor
-
GC39314
Tyrphostin AG1433
Tyrphostin AG1433 (AG1433, SU1433) is a selective platelet-derived growth factor receptor β (PDGFRβ) and vascular endothelial growth factor receptor 2 (VEGFR-2, Flk-1/KDR) inhibitor with IC50s of 5.0 μM and 9.3 μM, respectively.
-
GC45828
Ponatinib-d8
An internal standard for the quantification of ponatinib
-
GC38575
CP-547632 hydrochloride
A potent inhibitor of VEGFR2 and bFGF
-
GC38519
Ilorasertib hydrochloride
A multi-kinase inhibitor
-
GC38380
Vorolanib
X-82 (Vorolanib, CM082) is an oral, multikinase, dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) with antiangiogenic and antineoplastic activities.
-
GC37933
WHI-P180 hydrochloride
A multi-kinase inhibitor
-
GC37886
Vandetanib trifluoroacetate
A multi-kinase inhibitor
-
GC37808
Toceranib phosphate
A multi-targeted receptor tyrosine kinase inhibitor
-
GC37773
TG 100801 Hydrochloride
-
GC37772
TG 100572 Hydrochloride
-
GC37771
TG 100572
-
GC37665
Sorafenib (D4)
-
GC37664
Sorafenib (D3)
An internal standard for the quantification of sorafenib
-
GC37538
Ripretinib
A KIT and PDGFRα inhibitor
-
GC37047
Pz-1
-
GC36745
Nintedanib esylate
Nintedanib esylate, as a kinase inhibitor, used for the treatment of non-small cell lung cancer suffered from first-pass metabolism which resulted in low oral bioavailability .
-
GC36744
Ningetinib Tosylate
A multi-kinase inhibitor
-
GC36438
Lenvatinib mesylate
An inhibitor of VEGFR2 and VEGFR3
-
GC36203
GW806742X